Himadri Speciality Chemical: Monitoring Agency Report for Q1 FY2027 Confirms No Deviation in Fund Utilization
Himadri Speciality Chemical's Q1 FY2027 Monitoring Agency Report by ICRA confirms no deviation in fund utilization from its ₹341.8172 crore preferential issue. As of June 30, 2026, ₹267.9219 crore has been utilized. Unutilized proceeds of ₹73.8953 crore are in mutual funds and cash credit.
This is a standard regulatory filing and does not introduce any new material information that would significantly impact the company's stock or operations.
The report is a routine compliance filing confirming that the company is adhering to the utilization of funds as per the original plan. There is no new positive or negative development.
Himadri Speciality Chemical Limited has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations. The report, issued by ICRA Limited, confirms that the utilization of proceeds from the Preferential Issue of Warrants is in line with the objects of the issue, with no deviation observed.
The total issue size was ₹341.8172 crore, comprising 108,17,000 warrants at ₹316 each. As of June 30, 2026, the company has utilized ₹267.9219 crore of the total proceeds. Specifically, ₹185.0559 crore has been utilized for Capital Expenditure out of the originally proposed ₹256.8172 crore, and ₹82.8660 crore has been utilized for General Corporate Purposes out of the proposed ₹85.0000 crore.
The unutilized proceeds of ₹73.8953 crore are currently deployed in mutual funds (₹70.0000 crore) and a cash credit account (₹3.8953 crore). The company confirmed that the utilization of proceeds for both Capital Expenditure and General Corporate Purposes is on schedule, within the stipulated 12 months from the receipt of funds.
ICRA Limited, in its final monitoring agency report, stated that it does not constitute a commentary on the quality of the objects, appropriateness of costs, or assurance on the outcome of such spending. The report is based on information provided by the issuer and sources believed to be accurate, and ICRA does not perform an audit or independent verification.
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.